BCYC vs RGNX

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a remarkable 338.5% year-over-year revenue growth and strong analyst target price of $21.50 implying 210% upside, the company continues to report deep operating losses (-558.64% operating margin), deteriorating earnings (YoY EPS growth of -18.1%), and inconsistent earnings surprises, with only 1 out of the last 4 quarters beating estimates. High valuation multiples (Price/Sales of 17.01) contrast with negative profitability and weak insider sentiment, while recent insider selling adds downward pressure. Although the balance sheet appears strong with a current ratio of 10.66 and minimal debt, the lack of profitability and cash flow transparency limits confidence in sustainable recovery.

RGNX exhibits significant financial fragility, evidenced by a weak Piotroski F-Score of 3/9 and a lack of deterministic value markers like the Graham Number. While the company shows strong top-line revenue growth of 43%, this is offset by severe profitability deficits, including a profit margin of -113.75% and consistent earnings misses over the last four quarters. The stark divergence between the current price ($9.49) and the analyst target ($27.82) suggests a speculative valuation based on future pipeline success rather than current fundamentals. High debt-to-equity (2.54) and bearish insider sentiment further compound the risk profile.